Etanercept and methotrexate in rheumatoid arthritis [2] (multiple letters)

Lancet

Volumn 363, Issue 9422, 2004, Pages 1733-1734

  Malgarini, Renato Bertini ^a   Pimpinella, Giuseppe ^a   Klareskog, Lars ^b   Van Der Heijde, Désirée ^c   Fatenejad, Saeed ^d   Poteliakhoff, Alex ^e  

^a MINISTRY OF HEALTH   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d PFIZER INC   (United States)

^e Sudbury   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

ANEMIA; AUTOIMMUNITY; BLOOD DYSCRASIA; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; DRUG SAFETY; EOSINOPHILIA; HUMAN; LETTER; LEUKOCYTOSIS; LEUKOPENIA; LIFESTYLE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTOPENIA;

EID: 2442652490     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16264-8     Document Type: Letter

References (2)

1. L Klareskog van der Hiejde D de Jager JP Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomised controlled trial Lancet 363 2004 675 681
2. EMEA Revised EMEA public statement on etanercept (Enbrel): serious hematological reactions and demyelination disorders http://www.emea.eu.int/pdfs/human/press/pus/3087100en.pdf (accessed Mar 12, 2004).